AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04653870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cyriax manipulation lumber
Description: In group A patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Cyriax manipulation.~Exercises (Guided low back exercises, 3-5times/day). Ankle pumping (5-10 repetition with 15-20 second hold), Quads Isometric (5-10 repetition with 15-20 second hold), Hams \& Calf stretching (5-10 repetition with 15-20 second hold), Bridging (5-10 repetition with 15-20 second hold), Prone Back extension (10 repetition) Precaution Prevent yourself from sitting low on ground, Sitting with support will be directed and be careful during driving and ascending stairs.~Cyriax Manipulation: 2-3 repetitions/session, 2 session/week Lumbar spinal manipulation Rotation Techniques Lumbar spinal manipulation Extension Techniques Lumbar spinal manipulation Antideviation Techniques total of 4 session were given. 2 session/week.
Study NCT02582242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.
Study NCT02582242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.
Study NCT00862823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir, emtricitabine and efavirenz fixed dose tablet
Description: Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
Study NCT00862823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir, emtricitabine and efavirenz tablet added to solution
Description: Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
Study NCT02653144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: local anesthetics adjuvants. Ropivacaine 0.5% 20ml. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
Study NCT04653870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumber decompression
Description: Group B: In group B patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Decompression Session.~Conservative therapy: Same as Group A~Lumbar spine decompression:~30 Minutes Session (generalized time for every one) . On the account of MRI description level is recommended and acknowledged by MRI the level of disc protrusion, decompression is operated. Patient is lying on table facing upward. For locking of the patient's body it was secured by pelvis and thoracic straps. One part of the decompression table is immobile other is movable. Bottom extreme part of the table is mobile.~Estimation of weight of patient is first thing to do. We calculated it by division of whole weight by 5 and that 5th segment of weight was utilized as an interventional pound for decompression. .
Study NCT02653144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: local anesthetics adjuvants. Ropivacaine 0.5% 20ml. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
Study NCT02653144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: local anesthetics adjuvants. 75mcg of dexmedetomidine. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
Study NCT02653144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: local anesthetics adjuvants. 4mg dexamethasone. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
Study NCT04152070 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention to be administered, only collection of data through various tests and questionnaires.
Study NCT02746978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peer directed education
Description: No drug or device is included. The intervention of interest is the redesigned approach to inpatient education that follows the Stanford chronic disease self management approach which includes peer-led problem solving discussions compared to traditional didactic education lectures provided by nurse educators
Study NCT02746978 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient Engagement Portal
Description: No drug or device interventions. The Engagement Portal is populated by electronic medication record information (demographics, medications, supplies) then owned/maintained by patient after discharge. This approach to managing information and conditions associated with injury will be compared to the traditional approach of providing patients with a large instruction manual to carry home with them.
Study NCT03547011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US guided Quadratus Lumborum block
Description: Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
Study NCT03547011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US guided Paravertebral block.
Description: Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
Study NCT02807727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
Study NCT02807727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modified Ringers Lactate
Description: Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
Study NCT02758938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urologic biofeedback software
Description: All subjects (end users) will be walked through the urologic biofeedback software training suite. Each end user will follow a protocol that is specific to their role. Upon completing their session(s) with the software, each end user will provide appropriate feedback.
Study NCT00582608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-8H9
Description: This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m\^2 dose \[intended specific activity of \~20 mCi/mg protein\]
Study NCT00582608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8H9
Description: administration of 50mg/1.73m\^2 of unlabeled 8H9.
Study NCT01733667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediENT
Description: MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
Study NCT01733667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MeroPack
Description: MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
Study NCT03229252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhalation Solution
Description: Normal Saline Inhalation Solution
Study NCT03229252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPX-101
Description: SPX-101 Inhalation Solution
Study NCT03356938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Restricted sleep to 5 hours / night for 5 days prior to sleep laboratory examination
Study NCT03356938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Sleep deprivation during first night of sleep laboratory examination
Study NCT03171038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Study NCT05533008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 0.5 mcg/kg
Description: IV CR845 0.5 mcg/kg as a bolus injection
Study NCT05533008 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Placebo as a bolus injection
Study NCT00820248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given IV
Study NCT02473510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: A single dose of 10\^(7.0 ± 0.5) FFU per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
Study NCT02473510 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
Study NCT00820248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV
Study NCT00820248 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Description: Patients undergo radiotherapy
Study NCT00820248 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Patients undergo radiotherapy
Study NCT00820248 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated radiation therapy
Description: Patients undergo accelerated fractionation radiotherapy
Study NCT00820248 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: Patients undergo radiotherapy
Study NCT00820248 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Patients undergo radiotherapy
Study NCT01980459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: magnesium lactate
Description: Patient will be given 4 tablets a day of study supplement (Magnesium Lactate) for 3 months. Magnesium cellular and serum levels will be compared prior and post intervention.
Study NCT01415713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1,Leucovorin,Oxaliplatin,Gemcitabine
Description: Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma
Study NCT03973879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: Oncolytic polio/rhinovirus recombinant
Study NCT01417897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
Study NCT01417897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
Study NCT01417897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular human insulin
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
Study NCT03973879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Antibody
Study NCT03753464 — intervention group
Intervention type: PROCEDURE
Intervention: Gingival biopsy and blood sample collection
Description: Gingival and blood samples will be collected.
Study NCT02919319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 (Formulation A)
Description: Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg
Study NCT02919319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 (Formulation B)
Description: Soft gelatin capsules for oral administration formulated at the strength of 25 mg
Study NCT03745625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h.
Study NCT03745625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: First-stage: after an initial dose of 5mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: loading dose of 1mg/kg given over 1 minute, then a continuous infusion of maintenance dose 1.75 mg/kg/h for a total infusion time of 12h.
Study NCT02919319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Formulation A)
Description: Hard capsules matching ACT-541468 Formulation A
Study NCT02919319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Formulation B)
Description: Soft capsules matching ACT-541468 Formulation B
Study NCT02919319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled ACT-541468
Description: Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously
Study NCT02919319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tracer
Description: Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.
Study NCT02924285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure (Radiofrequency catheter ablation)
Description: Radiofrequency catheter ablation
Study NCT02924285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Amiodarone, Verification of superiority of catheter ablation over amiodarone for treatment of PVCs in patients with structural heart disease as:~Antiarrhythmic Drug Amiodarone
Study NCT03138759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Orally, on Day 2
Study NCT03138759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Orally, on Day 2
Study NCT01636180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
Study NCT03232879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R).
Study NCT03232879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation
Description: Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R). Before the subjects performed the mental MI practice, they were presented with a 30 seconds video that displayed the task that they ought to imagine later. A video was played prior to the first practice of imagination and after the second mental practice, a second video was shown.
Study NCT01046903 — intervention group
Intervention type: DRUG
Intervention: Fragmin® (Dalteparin Sodium)
Description: Administered per prescribing physician
Study NCT02285166 — intervention group
Intervention type: DRUG
Intervention: Omega-3 fatty acid ethyl esters
Description: Omega-3 fatty acid ethyl esters granular capsules
Study NCT02285166 — intervention group
Intervention type: DRUG
Intervention: Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).
Study NCT05366348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recreational activity
Description: Horse-back riding
Study NCT03110406 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: whole-body vibration training
Description: Training on the Vibrating platform will be performed with the patients in the static position.The exercises will be performed in the first two weeks for 10 minutes consisting of 60 seconds of low intensity and 30 seconds of standing rest in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. Monitoring of blood pressure, heart rate and peripheral oxygen saturation should be done every 5 minutes.
Study NCT03110406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole-body vibration training
Description: Training on the Vibrating platform will be performed with the patients in the static position.The exercises will be performed in the first two weeks for 10 minutes consisting of 60 seconds of low intensity and 30 seconds of standing rest in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. Monitoring of blood pressure, heart rate and peripheral oxygen saturation should be done every 5 minutes.
Study NCT02097563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Training
Description: This is a training method involving a live workshop followed by high intensity technical consultation.
Study NCT02097563 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Training
Description: Clinicians complete an online workshop in family-focused therapy, followed by technical consultation sessions after every third session.
Study NCT00616343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide
Description: 100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
Study NCT00300885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel
Description: Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), \[400 mg orally, twice daily\] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
Study NCT00300885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin plus Paclitaxel
Description: Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily\] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
Study NCT00795470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial
Description: Appropriate antimicrobial based on urine culture results
Study NCT00795470 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter change
Description: Change urine catheter
Study NCT04274673 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: measuring cotinine level
Description: Measuring of the cotinine levels
Study NCT03157271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intramuscular Dry Needling
Description: Dry Needling is a procedure in which a solid filament needle is inserted into the skin and muscle directly at a myofascial trigger point. A myofascial trigger point consists of multiple contraction knots, which are related to the production and maintenance of the pain cycle and interfere with movement patterns.
Study NCT02729051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains UMEC and VI blended with lactose and magnesium stearate. It is available as dry white powder, 62.5 mcg per blister UMEC, 25 mcg per blister VI. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
Study NCT02729051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/VI
Description: This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains VI blended with lactose and magnesium stearate. It is available as dry white powder, 25 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
Study NCT02729051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UMEC
Description: This intervention is available in one strip. The strip contains UMEC blended with lactose and magnesium stearate. The formulation is available as dry white powder, 62.5 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
Study NCT02729051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This intervention is available in one strip. The strip contains lactose. The formulation is available as dry white powder. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).